MENU
BAX
Stock ticker: NYSE
PRICE
CHANGE
CAPITALIZATION

BAX stock forecast, quote, news & analysis

Baxter offers a variety of medical supplies and equipment to providers... Show more

BAX
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
Interact to see
Advertisement

Why Baxter International Inc. (BAX) Stock Is Up +17% in the Last 30 Days

Key Takeaways

  • BAX shares rose approximately 17% over the last 30 days, advancing from near $18.78 in late May 2026 to $22.04 by June 26, 2026.
  • The stock has shown recovery momentum within a broader 52-week range of $15.73 to $31.76.
  • Recent quarterly trends reflect ongoing turnaround efforts amid industry challenges in medical instruments and supplies.
  • Key influencing factors include broader market sentiment, sector positioning, and company-specific operational updates.
  • Investors continue to monitor Baxter’s multi-pronged strategy for margin improvement and regulatory navigation.

Baxter International Inc. (BAX) Company Overview and Market Position

Baxter International Inc. develops, manufactures, and markets products for hemophilia, kidney disease, immune disorders, and other chronic conditions. The company operates in the medical instruments and supplies industry, offering a portfolio that includes renal care, medication delivery, and surgical products. Baxter maintains a global presence with established distribution networks and focuses on innovation in patient care solutions. Investors track the stock for its exposure to healthcare demand trends and its competitive positioning against peers in specialized medical devices and therapies.

Baxter International Inc. (BAX) Stock Price Performance: Last 30 Days vs. Quarter

Over the last 30 days, BAX advanced from a closing level near $18.78 on May 29, 2026, to $22.04 on June 26, 2026, representing an approximate gain of 17%. This move occurred within a trading environment where the stock fluctuated between daily lows near $21.43 and highs near $22.18 in recent sessions. On a quarterly basis, the performance aligns with a recovery pattern from earlier 2026 lows, though longer-term annual returns have varied significantly in prior years.

What Drove BAX Stock Price in the Last 30 Days

The recent price appreciation reflects a combination of market recovery dynamics and company-specific developments within the healthcare sector. Broader sentiment toward medical device and supplies companies, along with operational progress in Baxter’s turnaround initiatives, contributed to improved investor positioning. Volume patterns and price stabilization around recent levels supported the upward trajectory without reliance on single-event catalysts.

What Drove BAX Stock Performance Over the Last Quarter

The quarterly narrative centers on Baxter’s ongoing efforts to stabilize operations and address margin pressures in a competitive landscape. Developments in renal care and medication delivery segments, combined with strategic adjustments, have shaped investor views. The stock’s movement fits within a multi-month recovery from depressed levels, influenced by sector rotation and macroeconomic factors affecting healthcare equities.

Trending AI Robots

Tickeron’s Trending AI Robots page showcases a curated selection of top-performing AI trading bots from hundreds available across thousands of tickers. Only the most relevant and highest-performing strategies appear in this section, with bots differing in approach, holding periods, and performance metrics. Users can explore these automated trading options to gain insights into various market opportunities. Trending AI Robots

BAX Stock Forecast Drivers: What Investors Should Watch Next

Investors should monitor upcoming earnings reports, updates on guidance, regulatory developments in medical products, and shifts in demand for renal and surgical solutions. Macroeconomic conditions, competitive dynamics within the supplies sector, and institutional activity remain relevant factors. Analyst expectations and industry trends will continue to influence sentiment.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
A.I.Advisor
a Summary for BAX with price predictions
Jul 02, 2026

Aroon Indicator for BAX shows an upward move is likely

BAX's Aroon Indicator triggered a bullish signal on July 02, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 172 similar instances where the Aroon Indicator showed a similar pattern. In of the 172 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for BAX just turned positive on June 24, 2026. Looking at past instances where BAX's MACD turned positive, the stock continued to rise in of 46 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where BAX advanced for three days, in of 287 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BAX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

BAX broke above its upper Bollinger Band on June 26, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. BAX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.680) is normal, around the industry mean (4.514). P/E Ratio (87.846) is within average values for comparable stocks, (182.651). BAX's Projected Growth (PEG Ratio) (36.677) is very high in comparison to the industry average of (3.431). Dividend Yield (0.010) settles around the average of (0.025) among similar stocks. P/S Ratio (0.892) is also within normal values, averaging (76.829).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BAX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.

A.I.Advisor
published Dividends

BAX paid dividends on July 01, 2026

Baxter International BAX Stock Dividends
А dividend of $0.01 per share was paid with a record date of July 01, 2026, and an ex-dividend date of May 29, 2026. Read more...
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Intuitive Surgical (NASDAQ:ISRG), Align Technology (NASDAQ:ALGN).

Industry description

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

Market Cap

The average market capitalization across the Pharmaceuticals: Other Industry is 8.21B. The market cap for tickers in the group ranges from 126 to 150.88B. ISRG holds the highest valuation in this group at 150.88B. The lowest valued company is HGYMF at 126.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Other Industry was 3%. For the same Industry, the average monthly price growth was 6%, and the average quarterly price growth was -5%. ZTEK experienced the highest price growth at 26%, while NNNN experienced the biggest fall at -10%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Other Industry was 83%. For the same stocks of the Industry, the average monthly volume growth was 25% and the average quarterly volume growth was 136%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 58
P/E Growth Rating: 66
Price Growth Rating: 54
SMR Rating: 84
Profit Risk Rating: 96
Seasonality Score: 14 (-100 ... +100)
View a ticker or compare two or three
BAX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

a provider of a portfolio of essential renal and hospital products, including acute and chronic dialysis, sterile IV solutions, infusion systems and devices

Industry PharmaceuticalsOther

Profile
Details
Industry
Medical Specialties
Address
One Baxter Parkway
Phone
+1 224 948-2000
Employees
60000
Web
https://www.baxter.com
Why Baxter International Inc. (BAX) Stock Is Up +17% in the Last 30 Days